Clinical TrialJun 2, 2026, 04:31 PM
Tenaya to Report Interim MyPEAK-1 Phase 1b/2 Trial Data June 3
AI Summary
Tenaya Therapeutics announced it will report new interim data from Cohort 1 and Cohort 2 of its MyPEAK™-1 Phase 1b/2 trial for TN-201 gene therapy on Wednesday, June 3, 2026. The data, concerning adults with MYBPC3-associated hypertrophic cardiomyopathy (HCM), will be reviewed during a live webcast. TN-201, designed to address the underlying genetic cause of HCM, has received Fast Track, Orphan Drug, and Rare Pediatric Drug Designations from the U.S. FDA, and orphan medicinal product status from the European Commission.
Key Highlights
- Tenaya to report new interim data from MyPEAK™-1 Phase 1b/2 trial.
- Data concerns TN-201 gene therapy for MYBPC3-associated hypertrophic cardiomyopathy (HCM).
- Webcast for data review scheduled for June 3, 2026, at 8:00 a.m. ET.
- MYBPC3 variants account for approximately 20% of HCM, affecting 120,000 US patients.
- TN-201 has US FDA Fast Track, Orphan Drug, and Rare Pediatric Drug Designations.
- TN-201 also received orphan medicinal product status from the European Commission.
Price Impact
More from TNYA